Evidence map›Paper›PMID 33805518›Full record

ArticleCancers2021

Ander Saenz-Antoñanzas, Veronica Moncho-Amor, Jaione Auzmendi-Iriarte, Alejandro Elua-Pinin, Karine Rizzoti, Robin Lovell-Badge, Ander Matheu

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. TheiScience · 2026
    Article
  2. Article
  3. The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. EditingInternational journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ander Saenz-AntoñanzasCellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain.
Veronica Moncho-AmorStem Cell Biology and Developmental Genetics Lab, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-7914-6683
Jaione Auzmendi-IriarteCellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain.
Alejandro Elua-PininCellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain.
Karine RizzotiStem Cell Biology and Developmental Genetics Lab, The Francis Crick Institute, London NW1 1AT, UK.
Robin Lovell-BadgeStem Cell Biology and Developmental Genetics Lab, The Francis Crick Institute, London NW1 1AT, UK.ORCID 0000-0001-9364-4179
Ander MatheuCellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain.
Biogipuzkoa Health Research Institute · ESThe Francis Crick Institute · GBIkerbasque · ES

Funding

Instituto de Salud Carlos III PI16/01580Instituto de Salud Carlos III PI19/01355
6 · The paper itself

Abstract

SOX2 is a transcription factor associated with stem cell activity in several tissues. In cancer, SOX2 expression is increased in samples from several malignancies, including glioblastoma, and high SOX2 levels are associated with the population of tumor-initiating cells and with poor patient outcome. Therefore, understanding how SOX2 is regulated in cancer cells is relevant to tackle tumorigenesis. The

Indexed as

cancer stem cellsglioblastomassignalingSOX2SRR2

Identifiers

PMID33805518
PMCPMC8037847
OpenAlexW3151029159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.